BusinessZomato-backed fitness startup's losses rise 42% by The Tamesis Zomato-backed fitness startup CureFit reported a 42% jump in losses despite a 33.6% growth in revenue for FY24. Post Views: 102 Share this Facebook X Telegram Whatsapp Email TagsFitnesslossesrisestartup39sZomatobackedRelated Posts Beyond bamboo diplomacy: Vietnam’s era of national rise in a volatile world January 22, 2026 Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes. January 20, 2026 Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes. January 19, 2026 The TamesisLeave a Reply Cancel replyYour email address will not be published. Save my name, email, and website in this browser for the next time I comment. Previous StoryBYD plans to recruit graduates from around the world for robotics research Next StorySouth Korean President Yoon Eun-hye was impeached. What happens to all the benefits? Latest from Blog Workers’ Party rejects Singapore PM Wong’s invitation to nominate another elected MP as Leader of the Opposition by The Tamesis Healthcare IT spending hits $961b by 2030 by The Tamesis Vietnam under leader To Lam eyes China-style strongman model, 10% growth push by The Tamesis Billionaire Jeffrey Cheah’s Sunway Proceeding With $2.7 Billion IJM Takeover Despite Money-Laundering Probe by The Tamesis Is 2026 the Year Fashion Finally Fixes Its Returns Problem? by The Tamesis How Brands Can Navigate Tariff Unpredictability in 2026 by The Tamesis Japan’s ruling party set to announce election pledges, consider pause on consumption tax for food by The Tamesis “We’re Going Back to Basics”: What’s Next for YMC by The Tamesis Heavyweights enter Nepal’s electoral race, while some sit out by The Tamesis Beyond bamboo diplomacy: Vietnam’s era of national rise in a volatile world by The TamesisRelated Posts Beyond bamboo diplomacy: Vietnam’s era of national rise in a volatile world January 22, 2026 Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes. January 20, 2026 Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes. January 19, 2026 Previous StoryBYD plans to recruit graduates from around the world for robotics research Next StorySouth Korean President Yoon Eun-hye was impeached. What happens to all the benefits?
Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes. January 20, 2026
Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes. January 19, 2026
Workers’ Party rejects Singapore PM Wong’s invitation to nominate another elected MP as Leader of the Opposition by The Tamesis
Billionaire Jeffrey Cheah’s Sunway Proceeding With $2.7 Billion IJM Takeover Despite Money-Laundering Probe by The Tamesis
Japan’s ruling party set to announce election pledges, consider pause on consumption tax for food by The Tamesis
Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes. January 20, 2026
Singapore’s biomedical sector is expected to benefit after a sharp rise in pharmaceutical production, as companies anticipate US trade policy changes. January 19, 2026